MidEuropa’s Post

If you're attending the Expanded Access Programs World Congress next week in London, definitely find time to check out Ana Paula Tediosi's presentation, or catch her during the conference. Ana is a wealth of knowledge when it comes to end to end strategy for all types of access programs (among so many other things)! #earlyaccessprograms, #expandedaccess, #posttrialaccess, #compassionateuse, #clinicaltrials WEP Clinical

CVC Capital Partners, a Luxembourg-based private equity and investment advisory firm, agreed to acquire the Therakos business of Mallinckrodt Pharmaceuticals, a global specialty pharmaceutical company, for $925m. "Today's announcement underscores our commitment to executing on our strategic priorities and creating value for our stakeholders. This transaction provides the Therakos business with an ideal partner to invest in its continued growth, and we look forward to closely working with CVC to transition Therakos for the benefit of patients, healthcare providers, partners and employees. I thank the Therakos team for their ongoing commitment and dedication to improving the lives of patients," Sigurdur Olafsson, Mallinckrodt President and CEO. Mallinckrodt is advised by Lazard, A&O Shearman, Arthur Cox LLP, Wachtell, Lipton, Rosen & Katz (led by Victor Goldfeld) and Joele Frank (led by Michael Freitag, Aaron Palash and Aura Reinhard). CVC Capital is advised by Candesic, PwC, UBS and Freshfields Bruckhaus Deringer. #MergersAcquisitionsDivestitures #PrivateEquity #Pharmaceutical

The long-term care market is currently experiencing a trend of increasing consolidation. By building solid relationships with these key players, pharmaceutical companies can streamline their efforts and meet patients' needs more effectively. As market consolidation continues, the potential for impactful partnerships and growth in this space becomes even more promising. Stay connected with Life Sciences by PointClickCare on LinkedIn for the newest developments and expert content. #LongTermCare #Healthcare #StrategicPartnerships

🌟"Redefining Value" in the Pharma Industry: Excited to have been part of the 𝟭𝘀𝘁 𝗦𝗙𝗘𝗘 𝗦𝘂𝗺𝗺𝗶𝘁🌟 Our Partner, Angelos Benos, Pharma & Healthcare Industry Lead at PwC Greece, took the stage yesterday at the 1st SFEE Summit, during an intriguing panel on “𝗘𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 & 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗥&𝗗”💡Angelos contributed valuable insights and added depth to a discussion concerning investments of the Pharmaceutical sector in R&D and in particular Clinical Trials. Clinical trials represent a very significant Foreign Direct Investment pot that our country unfortunately has historically failed to claim its fair share and Angelos put forward certain policy initiatives that can help boost competitiveness and attract R&D investments by the Big-Pharma. #PwCGreece #SFEESummit2024 #HealthcareInnovation #GreekPharma

Sanofi in Talks to Sell Majority Stake in Opella to Clayton Dubilier & Rice 💼💊 Sanofi (SASY.PA) is in discussions to sell a 50% controlling stake in its consumer healthcare unit, Opella, to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The deal, estimated at €15 billion ($16.41 billion) 💶, aims to help Sanofi refocus on its core pharmaceutical business and new drug development. Opella, which employs over 11,000 people 👥 and owns popular brands like Doliprane 💊, has attracted bids from both CD&R and PAI Partners. The French finance ministry supports CD&R’s bid but requires commitments to keep Opella's headquarters and operations in France. #Sanofi #Opella #PharmaNews #PrivateEquity #HealthcareBusiness #PharmacyStudent #HealthcareTransformation

🌟"Redefining Value" in the Pharma Industry: Excited to have been part of the 𝟭𝘀𝘁 𝗦𝗙𝗘𝗘 𝗦𝘂𝗺𝗺𝗶𝘁🌟 Our Partner, Angelos Benos, Pharma & Healthcare Industry Lead at PwC Greece, took the stage yesterday at the 1st SFEE Summit, during an intriguing panel on “𝗘𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 & 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗥&𝗗”💡Angelos contributed valuable insights and added depth to a discussion concerning investments of the Pharmaceutical sector in R&D and in particular Clinical Trials. Clinical trials represent a very significant Foreign Direct Investment pot that our country unfortunately has historically failed to claim its fair share and Angelos put forward certain policy initiatives that can help boost competitiveness and attract R&D investments by the Big-Pharma. #PwCGreece #SFEESummit2024 #HealthcareInnovation #GreekPharma

Our Annual Report is fresh off the press! Grünenthal's people have transformed our company over the last few years, uniquely positioning us to meet the increased demand for better pain treatments. 🌎 Our medicines today help more patients than ever before as we are growing our footprint in key pharmaceutical markets, especially in the United States 🧬 We advanced key R&D projects, creating one of the strongest pain-focused pipelines in the industry 📦 We ensured uninterrupted supply of medicines to patients in over 100 countries 💊 Through strategic acquisitions, we expanded our portfolio of established medicines This momentum put us in an excellent position to deliver outstanding business performance.  Read more about our story of transformation in our Annual Report: https://bit.ly/3UklN84 #WeAreGrünenthal #WorldFreeofPain

It is here, and it is real. The #inflationreductionact, learn more how to navigate the various complex dynamics from our experts, Scott Briggs, Thomas Marder, Matthew Riordan

👏 With most payments businesses turning their backs on the #pharmacy sector (not naming any names), Ryft is proudly partnering with incredible pharmacy platforms such as Charac - The Pharmacy App to deliver a modern payment experience at exceptional rates for this essential industry. If you are interested to find out more, please ping me or one of the team! #pharmacy #payments #fintech